Search research articles
Contact Us
Filters
Showing results (91-100 of 173) with videos related to
Page
of 18
Sort By:
Cytokines and Molecular Therapy
|
December 1, 1996
Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth
H Bohlen, K Thielemanns, H Tesch, et al.
Nuklearmedizin. Nuclear Medicine
|
September 16, 2005
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives]
K Schomäcker, M Dietlein, R Schnell, et al.
International Journal of Cancer
|
May 8, 2000
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice
S Barth, M Huhn, B Matthey, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 14, 2012
Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group
J Kriz, C Bangard, U Haverkamp, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 12, 2012
Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma. Is the definition on the basis of a chest radiograph in the era of CT obsolete?
J Kriz, R-P Mueller, H Mueller, et al.
Cancer Research
|
December 26, 2001
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma
M Huhn, S Sasse, M K Tur, et al.
Journal of Immunological Methods
|
February 27, 2001
Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells
K Sundarapandiyan, T Keler, D Behnke, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
April 23, 2013
The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists
H T Eich, J Kriz, H Schmidberger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 1992
Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice
U Kapp, J Wolf, C von Kalle, et al.
Leukemia & Lymphoma
|
April 30, 1999
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma
M Reiser, A Josting, P Dias Wickramanayake, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 173) with videos related to
Sort By:
Page
of 18
Cytokines and Molecular Therapy
|
December 1, 1996
Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth
H Bohlen, K Thielemanns, H Tesch, et al.
Nuklearmedizin. Nuclear Medicine
|
September 16, 2005
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives]
K Schomäcker, M Dietlein, R Schnell, et al.
International Journal of Cancer
|
May 8, 2000
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice
S Barth, M Huhn, B Matthey, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
June 14, 2012
Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group
J Kriz, C Bangard, U Haverkamp, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 12, 2012
Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma. Is the definition on the basis of a chest radiograph in the era of CT obsolete?
J Kriz, R-P Mueller, H Mueller, et al.
Cancer Research
|
December 26, 2001
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma
M Huhn, S Sasse, M K Tur, et al.
Journal of Immunological Methods
|
February 27, 2001
Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells
K Sundarapandiyan, T Keler, D Behnke, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
April 23, 2013
The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists
H T Eich, J Kriz, H Schmidberger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 1992
Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice
U Kapp, J Wolf, C von Kalle, et al.
Leukemia & Lymphoma
|
April 30, 1999
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma
M Reiser, A Josting, P Dias Wickramanayake, et al.
Page
of 18